WMT

125.97

-0.39%↓

COST

992.22

-0.28%↓

163.38

-1.36%↓

80.25

-0.58%↓

190.33

+2.02%↑

WMT

125.97

-0.39%↓

COST

992.22

-0.28%↓

163.38

-1.36%↓

80.25

-0.58%↓

190.33

+2.02%↑

WMT

125.97

-0.39%↓

COST

992.22

-0.28%↓

163.38

-1.36%↓

80.25

-0.58%↓

190.33

+2.02%↑

WMT

125.97

-0.39%↓

COST

992.22

-0.28%↓

163.38

-1.36%↓

80.25

-0.58%↓

190.33

+2.02%↑

WMT

125.97

-0.39%↓

COST

992.22

-0.28%↓

163.38

-1.36%↓

80.25

-0.58%↓

190.33

+2.02%↑

Home・Akciju saraksts・USANA Health Sciences Inc

USANA Health Sciences Inc

Atvērts

21.3 -0.47

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

20.59

Max

21.57

Galvenie mērījumi
By Trading Economics
Ienākumi	-17M -6.7M
Pārdošana	-22M 214M
P/E Sektora vidējais	23.222 32.9
EPS	-0.15
Peļņas marža	-3.118
Darbinieki	1,700
EBITDA	-17M 11M

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 21. apr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	371K 382M
Iepriekšējā atvēršanas cena	21.77
Iepriekšējā slēgšanas cena	21.3

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

28.405 / 29.84 Atbalsts un pretestība

USANA Health Sciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 24. febr. 23:07 UTC

Peļņas

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

2026. g. 24. febr. 23:01 UTC

Peļņas

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

2026. g. 24. febr. 22:59 UTC

Peļņas

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

2026. g. 24. febr. 22:42 UTC

Peļņas

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

2026. g. 24. febr. 22:24 UTC

Iegādes, apvienošanās, pārņemšana

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

2026. g. 24. febr. 23:46 UTC

Tirgus saruna

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

2026. g. 24. febr. 23:36 UTC

Tirgus saruna

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

2026. g. 24. febr. 23:30 UTC

Tirgus saruna

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

2026. g. 24. febr. 23:20 UTC

Tirgus saruna

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

2026. g. 24. febr. 23:20 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 24. febr. 23:16 UTC

Peļņas

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

2026. g. 24. febr. 23:13 UTC

Peļņas

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

2026. g. 24. febr. 23:12 UTC

Peļņas

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

2026. g. 24. febr. 23:10 UTC

Peļņas

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

2026. g. 24. febr. 23:10 UTC

Peļņas

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

2026. g. 24. febr. 23:08 UTC

Peļņas

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

2026. g. 24. febr. 23:07 UTC

Peļņas

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

2026. g. 24. febr. 22:52 UTC

Peļņas

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

2026. g. 24. febr. 22:46 UTC

Peļņas

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

2026. g. 24. febr. 22:31 UTC

Iegādes, apvienošanās, pārņemšana

Warner Receives New Bid From Paramount -- 3rd Update

2026. g. 24. febr. 22:29 UTC

Peļņas

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

2026. g. 24. febr. 22:28 UTC

Peļņas

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

2026. g. 24. febr. 22:27 UTC

Peļņas

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

2026. g. 24. febr. 22:27 UTC

Peļņas

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

2026. g. 24. febr. 22:25 UTC

Peļņas

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

2026. g. 24. febr. 22:24 UTC

Peļņas

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

2026. g. 24. febr. 22:23 UTC

Peļņas

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

2026. g. 24. febr. 22:22 UTC

Peļņas

Woolworths Interim Dividend 45 Australian Cents/Share

2026. g. 24. febr. 22:22 UTC

Peļņas

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

2026. g. 24. febr. 22:21 UTC

Peļņas

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Salīdzinājums

Cenas izmaiņa

USANA Health Sciences Inc Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam USANA Health Sciences Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

28.405 / 29.84Atbalsts un pretestība

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There are no events.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par USANA Health Sciences Inc

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products through retail stores and online. The company has a research collaboration agreement with Beijing University of Chinese Medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.